From: Designing the next generation of medicines for malaria control and eradication
Stage | Cumulative success rates (CMR) | Cumulative success rates (MMV) | Cost per stage (MMV)b/ millions USD |
---|---|---|---|
Preclinical | 4.4% | 12% | 1.8 |
Phase I | 8% | 23% | 1.5 |
Phase IIa | 15% | 34% | 5.4 |
Drug interactions/ Phase IIb | 51%a | 60% | 8.7 |
Phase III | 68% | 80% | 31.0c |
Submission | 96% | 100% | 2.0 |